132 related articles for article (PubMed ID: 36367445)
1. Juvenile toxicity study of PF-07256472/recifercept, a recombinant human soluble fibroblast growth factor receptor 3, in 2-3-month-old cynomolgus monkeys.
Campion SN; Bowman CJ; Fuchs A; Karanian D; Rana P; Cappon GD
Birth Defects Res; 2023 Feb; 115(3):348-356. PubMed ID: 36367445
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Imaging of the Skull Base Synchondroses Demonstrate Prevention of a Premature Ossification After Recifercept Treatment in Mouse Model of Achondroplasia.
Rignol G; Garcia S; Authier F; Smith K; Tosello L; Marsault R; Dellugat P; Goncalves D; Brouillard M; Stavenhagen J; Santarelli L; Czech C; Gouze E
JBMR Plus; 2022 Feb; 6(2):e10568. PubMed ID: 35229060
[TBL] [Abstract][Full Text] [Related]
4. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
[TBL] [Abstract][Full Text] [Related]
5. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
[TBL] [Abstract][Full Text] [Related]
6. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
Breinholt VM; Rasmussen CE; Mygind PH; Kjelgaard-Hansen M; Faltinger F; Bernhard A; Zettler J; Hersel U
J Pharmacol Exp Ther; 2019 Sep; 370(3):459-471. PubMed ID: 31235532
[TBL] [Abstract][Full Text] [Related]
7. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
Wendt DJ; Dvorak-Ewell M; Bullens S; Lorget F; Bell SM; Peng J; Castillo S; Aoyagi-Scharber M; O'Neill CA; Krejci P; Wilcox WR; Rimoin DL; Bunting S
J Pharmacol Exp Ther; 2015 Apr; 353(1):132-49. PubMed ID: 25650377
[TBL] [Abstract][Full Text] [Related]
8. FGFR3 targeting strategies for achondroplasia.
Laederich MB; Horton WA
Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
[TBL] [Abstract][Full Text] [Related]
9. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.
Saint-Laurent C; Garcia S; Sarrazy V; Dumas K; Authier F; Sore S; Tran A; Gual P; Gennero I; Salles JP; Gouze E
PLoS One; 2018; 13(4):e0195876. PubMed ID: 29652901
[TBL] [Abstract][Full Text] [Related]
10. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
Matsushita M; Esaki R; Mishima K; Ishiguro N; Ohno K; Kitoh H
Sci Rep; 2017 Aug; 7(1):7371. PubMed ID: 28785080
[TBL] [Abstract][Full Text] [Related]
11. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
He L; Shobnam N; Wimley WC; Hristova K
J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
[TBL] [Abstract][Full Text] [Related]
12. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
Manickam K; Donoghue DJ; Meyer AN; Snyder PJ; Prior TW
Am J Med Genet A; 2014 Jan; 164A(1):243-50. PubMed ID: 24352917
[TBL] [Abstract][Full Text] [Related]
13. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
[TBL] [Abstract][Full Text] [Related]
14. Low bone mineral density in achondroplasia and hypochondroplasia.
Matsushita M; Kitoh H; Mishima K; Kadono I; Sugiura H; Hasegawa S; Nishida Y; Ishiguro N
Pediatr Int; 2016 Aug; 58(8):705-8. PubMed ID: 26716907
[TBL] [Abstract][Full Text] [Related]
15. Physical basis behind achondroplasia, the most common form of human dwarfism.
He L; Horton W; Hristova K
J Biol Chem; 2010 Sep; 285(39):30103-14. PubMed ID: 20624921
[TBL] [Abstract][Full Text] [Related]
16. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
18. PTH 1-34 Ameliorates the Osteopenia and Delayed Healing of Stabilized Tibia Fracture in Mice with Achondroplasia Resulting from Gain-Of-Function Mutation of FGFR3.
Chen H; Sun X; Yin L; Chen S; Zhu Y; Huang J; Jiang W; Chen B; Zhang R; Chen L; Nie M; Xie Y; Deng Z
Int J Biol Sci; 2017; 13(10):1254-1265. PubMed ID: 29104492
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
Webster MK; Donoghue DJ
EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
[TBL] [Abstract][Full Text] [Related]
20. Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.
Couser NL; Pande CK; Turcott CM; Spector EB; Aylsworth AS; Powell CM
Am J Med Genet A; 2017 Apr; 173(4):1097-1101. PubMed ID: 28181399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]